Sonnet BioTherapeutics Holdings, a clinical stage biotech based in Princeton, New Jersey, specializes in biologic medicines and has developed the FHAB technology for improved drug delivery in cancer treatment. Its lead assets include SON-1010 for solid tumors and SON-080 for chemotherapy-induced peripheral neuropathy.
Sonnet BioTherapeutics Holdings (SONN) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Sonnet BioTherapeutics Holdings's actual EPS was -$0.89, beating the estimate of -$0.94 per share, resulting in a 5.16% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
